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Introduction 
The minimal clinical important difference (MCID) is a useful and widely used concept to interpret the 
meaning of health-related quality of life (HRQoL) score changes. However, in order to give a greater 
sense of the meaning of score change across a wider spectrum of score changes, we propose a 
new concept of ‘2MCID’. This represents a score change of twice the MCID. This approach, novel in 
dermatology, has been used in other areas (1, 2) and highlights therapies that reach this higher 
change threshold. We hypothesise that this method would better discriminate between the efficacy 
of interventions to help guide clinical judgment and patient progress.  
 
HRQoL outcome measures are holistic, multi-faceted tools that capture several aspects of a 
patient’s overall well-being (3). Such measures are increasingly being implemented in interventional 
studies alongside clinical objective parameters as important contributors towards morbidity and 
mortality data (4). Reports of studies often include HRQoL data citing statistical differences pre- and 
post-intervention, though statistically significant changes may not be truly reflective of meaningful 
change in HRQoL, particularly within large sample sizes which may produce statistically significant 
change despite the change being small. (5) 
The MCID is described as the minimum difference needed for a patient to perceive the change as 
beneficial (6) and may be used to determine whether a medical intervention improves patient 
perceived outcomes. Factors to consider when calculating the MCID for a particular outcome 
include: patient baseline severity, particular disease or condition, patient demographics and 
treatment. As a result, there is no consensus on the best methodology for calculating the MCID (7), 
and values may therefore differ within the same population. Despite these limitations, it is still 
considered more useful for clinicians to assess the effectiveness of an intervention based on the 
patient’s perspective, rather than solely on statistical significance.  
Our recent systematic review demonstrated that the most commonly utilized QoL tool in 
dermatological trials is the Dermatology Life Quality Index (DLQI), with an MCID of 4 points (8, 9). 
While carrying out this systematic review it appeared that multiple MCID could provide a further aid 
to the interpretation of the results and we felt that this novel concept deserved further exploration. 
We have therefore applied the concept of 2MCID to data summarized in that review (8). 
 
Methods 
A systematic review was presented by Ali et al (8). We have introduced the concept of 2MCID to 
that dataset (i.e. DLQI score change of at least 8) to demonstrate comparative efficacy between 
interventions. 
 
Results 
A total of 100 trials were identified by the systematic review, covering a diverse range of 
interventions. As the DLQI was the most commonly used QoL measure (83% of studies), the 
2MCID concept was tested on interventions with documented DLQI scores. Figure 1 summarises all 
the interventions that met the different MCID thresholds. 
For topical treatments, clobetasol 0.05% spray showed the greatest improvement at 4 weeks 
(2MCID, 8 point improvement), followed by calcipotriol plus betamethasone at 8 weeks (6.4 points). 
These changes are comparable to ustekinumab 90 mg at 12 weeks (average 2MCID (8 point) 
improvement) and ciclosporin 3-5 mg/kg at 12 weeks (6.6 point improvement). No other topical 
therapy reached 2MCID. However, it is important to consider the context of baseline psoriasis 
severity, treatment duration and long-term QoL maintenance.  
Methotrexate 15 mg at 16 weeks was the only systemic intervention over the 2MCID threshold (8.7 
points). This was comparable to several biologics, including etanercept 50 mg at 24 weeks and 
ustekinumab 90 mg at 12 weeks (8.7points).  
 
Infliximab 5 mg/kg at 16 weeks and secukinumab 300 mg at 12 weeks on average demonstrated 
the largest improvement in DLQI score of 11.4 (>2MCID), just short of 3MCID. Amongst other 
interventions, an energy-restricted diet with immunosuppressive therapy at 24 weeks recorded 
DLQI improvement of 14.4 (3MCID). DLQI at 12 weeks improved by 11.2 (>2MCID) with PUVAsol 
0.6 mg/kg + isotretinoin 0.5 mg/kg: for PUVAsol alone, DLQI improvement was 6.8. 
 
For studies with treatment endpoint and assessment at 12 weeks, the interventions with the 
greatest average DLQI impact in each category were secukinumab 300 mg (2MCID, 11.4 points), 
ciclosporin 3-5 mg/kg (1MCID, 6.6 points), PUVAsol 0.6 mg/kg + isotretinoin 0.5 mg/kg (2MCID, 
11.2 points), Liquor Carbonis Distillate solution 15% (1MCID, 5.8 points) and educational 
programme (1MCID, 4 points).  
 
 
Discussion 
Previously, Leaf and Goldfarb (1) described the impact of erythropoiesis stimulating agents (ESAs) 
on HRQoL using Short-Form 36 (SF-36) and The Kidney Disease Questionnaire (KDQ). However, 
the authors only infrequently and arbitrarily refer to score changes for these measures using 
multiples of MCID without formal utilization of the concept. Similarly, Jones, Gelhorn (2) equate a 
change of ‘twice the MCID’ to a ‘large benefit’ when comparing active treatments for COPD against 
placebo using the St. George's Respiratory Questionnaire (SGRQ). However, neither study formally 
explored or stratified results using this concept. 
 
Although it is possible to apply score banding descriptors (10) to describe the number of patients 
within each score band pre and post intervention, there needs to be a method that can discriminate 
between the extent of the effect of interventions on QoL. The concept of ‘multiple-MCID’ could add 
meaning to score change when comparing therapies, and possibly when comparing results across 
different QoL instruments as a ‘unit of change’. The question may arise as to why 2MCID should be 
chosen rather than other multiples. 2MCID appears to be a practical threshold providing the 
potential of a meaningful ‘hurdle’ that developers of new interventions might strive to achieve. As 
indicated in the analysis of the systematic review, only one out of a hundred RCTs demonstrated a 
change of 3MCID indicating that a 3MCID ‘hurdle’ would be a difficult and impractical threshold to 
achieve. 
 
 
This ‘pilot study’ of the concept of ‘multiple-MCID’ demonstrates the potential benefit of comparing 
the extent of impact of different categories of interventions on QoL and interpreting change over 
time. For example, we have demonstrated that certain systemic interventions may impact QoL to 
the same extent as certain biologic treatments. Similarly, certain topical treatments may be as 
efficacious as systemic alternatives. Interpretation of these conclusions, however, should take into 
account that the dataset of the systematic review is not homogenous and often patients have 
different baseline severities. Furthermore, although MCID values are applied across a spectrum of 
scores in interpreting change in scores of a measure, in reality the MCID score value may be 
different depending on whether the score change is at the lower or upper end of a HRQoL measure 
score range. This criticism of the concept of MCID requires further investigation. One way to explore 
this would be through meta-regression where the magnitude of effect on DLQI is regressed on 
baseline severity. The concept of 2MCID may be too simplistic: ideally the identification and 
calculation of a multiple-MCID score should be based on prospective research that takes into 
account patient assessment of a higher level of change, using an anchor question based on, say, 
“Major clinically important difference”.  
 
Despite these reservations and investigation suggestions, as a ‘proof of concept’ we believe 
‘multiple-MCID’ provides additional meaningful information on clinical improvement and may be of 
value to clinicians, patients and the pharmaceutical industry. For example, medications that meet 
the ‘2MCID’ minimum threshold might be more easily approved by both pharmaceutical regulatory 
authorities and health technology assessment (HTA) agencies. This concept may also enable 
researchers to distinguish more efficiently between interventions and comparators in trials, 
potentially improving patients’ access to the most effective new medicines. Prospective longitudinal 
studies could aim to prove the usefulness of the concept before implementing it on a broader scale. 
Further work is required before this novel concept is adopted in treatment decision-making and in 
reimbursement appraisals. 
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Yinxieling formula at 8 weeks
XP-828L (Dermylex) 400 mg at 8 weeks
Voclosporin 0.4 mg/kg at 12 weeks
Voclosporin 0.3 mg/kg at 12 weeks
Voclosporin 0.2 mg/kg at 12 weeks
Voclosporin (ISA247) 1.5 mg/kg at 12 weeks
Voclosporin (ISA247) 0.5 mg/kg at 12 weeks
Ustekinumab 90 mg at 24 weeks
Ustekinumab 90 mg at 12 weeks
Ustekinumab 45 mg at 24 weeks
Ustekinumab 45 mg at 12 weeks
Ustekinumab 45-90 mg with immediate methotrexate withdrawal at 16 
weeks
Triamcinolone Acetonide 0.1% at 8 weeks
Tofacitinib 5 mg at 12 weeks
Tofacitinib 2 mg at 12 weeks
Tofacitinib 15 mg at 12 weeks
Sulphurous Mineral Waters Spray at 2 weeks
Secukinumab 300 mg at 12 weeks
Secukinumab 150 mg at 12 weeks
PUVAsol 0.6 mg/kg at 12 weeks
PUVAsol 0.6 mg/kg & Isotretinoin 0.5 mg/kg at 12 weeks
Placebo + nUVB at 24 weeks (compared with Methotrexate + nUVB)
Mometasone furoate 0.1% at 1 week
Mometasone furoate 0.1% + salicylic acid 5% at 1 week
Mindfulness-based cognitive therapy at 8 weeks
Methotrexate 7.5 mg at 16 weeks
Methotrexate 7.5 mg at 12 weeks
Methotrexate 15 mg at 16 weeks
Methotrexate 15 mg + nUVB at 24 weeks
Methotrexate + Folic Acid 5 mg at 12 weeks
Methotrexate (without Folic Acid) at 12 weeks
Low energy diet at 16 weeks
Low Dose Cytokines at 12 weeks
Liraglutide 1.8 mg at 8 weeks
Leflunomide 20 mg at 24 weeks
LCD Solution 15% at 12 weeks
Ixekizumab 75 mg at 8 weeks
Ixekizumab 25 mg at 8 weeks
Ixekizumab 150 mg at 8 weeks
Itolizumab 1.6 mg/kg at 12 weeks
Interdisciplinary dermatological and psychiatric care for psoriasis at 24 
weeks
Infliximab 5 mg/kg at 50 weeks
Infliximab 5 mg/kg at 24 weeks
Infliximab 5 mg/kg at 16 weeks
Infliximab 5 mg/kg at 14 weeks
Infliximab 5 mg/kg at 10 weeks
Infliximab 5 mg/kg at 100 weeks
Infliximab 3 mg/kg at 50 weeks
Infliximab 3 mg/kg at 10 weeks
Etanercept 50 mg at 54 weeks
Etanercept 50 mg at 24 weeks
Etanercept 50 mg at 12 weeks
Etanercept 50 mg + nUVB at 12 weeks (Patients who did not achieve 
PASI 90 after 12 weeks of Etanercept)
Etanercept 25 mg at 54 weeks
Etanercept 25 mg at 12 weeks
Etanercept 25 mg + continued methotrexate treatment
Etanercept 100 mg at 12 weeks
Etanercept + tapered methotrexate
Energy-restricted diet at 24 weeks
Efalizumab 1 mg/kg at 12 weeks
Educational Programme at 12 weeks
Educational Nursing Intervention at 6 weeks
Dermatological care for psoriasis at 24 weeks
DAB389IL-2 (5-15 mg/kg) at 4 weeks
Clobetasol Spray 0.05% at 4 weeks
Clobetasol Foam 0.05% at 2 weeks
Clobetasol Cream 0.05% at 2 weeks
Ciclosporin 3-5 mg/kg at 12 weeks
Chondroitin sulphate 800 mg at 12 weeks
Certolizumab 400 mg at 24 weeks
Certolizumab 400 mg at 12 weeks
Certolizumab 200 mg at 24 weeks
Certolizumab 200 mg at 12 weeks
Calcipotriol betamethasone at 8 weeks
Calcipotriol betamethasone at 4 weeks
Calcipotriol at 4 weeks
Calcipotriol 50 mcg/g at 8 weeks
Calcipotriene 0.005% at 12 weeks
Brodalumab 70 mg at 12 weeks
Brodalumab 280 mg at 12 weeks
Brodalumab 210 mg at 12 weeks
Brodalumab 140 mg at 12 weeks
Briakinumab 200 mg at 12 weeks
Briakinumab 100 mg at 40 weeks
Betamethasone valerate dressing at 4 weeks
Betamethasone at 8 weeks
Auricular Therapy + Yinxieling formula at 8 weeks
Apremilast 30 mg at 16 weeks
Apremilast 20 mg at 16 weeks
Apremilast 10 mg at 8 weeks
Aloe Vera 70% at 8 weeks
Alefacept 15 mg at 16 weeks
Alefacept 15 mg at 12 weeks
Alefacept 10 mg at 12 weeks
Adalimumab 80 mg at 24 weeks
Adalimumab 40 mg at 24 weeks
Adalimumab 40 mg at 16 weeks
Adalimumab 40 mg at 12 weeks
Adalimumab 40 mg + vehicle at 16 weeks
Adalimumab 40 mg + calcipotriol betamethasone at 16 weeks
Change in DLQI score from baseline
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